140 patents
Page 7 of 7
Utility
Cleavable Lipids
29 Jul 20
Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use.
Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
Filed: 12 Feb 20
Utility
Biodegradable Lipids for Delivery of Nucleic Acids
15 Jul 20
Frank DeRosa, Michael Heartlein
Filed: 21 Nov 19
Utility
Composition and Methods for Treatment of Primary Ciliary Dyskinesia
8 Jul 20
The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy.
Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
Filed: 6 Jan 20
Utility
Multimeric Coding Nucleic Acid and Uses Thereof
3 Jun 20
The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use.
Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
Filed: 13 Aug 19
Utility
Ice-based Lipid Nanoparticle Formulation for Delivery of Mrna
20 May 20
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid.
Frank DeRosa, Michael Heartlein, Shrirang Karve
Filed: 26 Jan 20
Utility
Methods and Compositions for Delivering Mrna Coded Antibodies
20 May 20
The present invention provides, among other things, methods and compositions for delivering an antibody in vivo by administering to a subject in need thereof one or more mRNAs encoding a heavy chain and a light chain of an antibody, and wherein the antibody is expressed systemically in the subject.
Michael Heartlein, Frank DeRosa, Anusha Dias, Braydon Charles Guild
Filed: 23 Jan 20
Utility
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
20 May 20
The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject.
SHRIRANG KARVE, FRANK DEROSA, MICHAEL HEARTLEIN, ZARNA PATEL
Filed: 20 Nov 19
Utility
Methods for Purification of Messenger Rna
25 Mar 20
The present invention provides, among other things, methods for purifying mRNA based on normal flow filtration for therapeutic use.
Joseph Parella, Kimberly Gillis, Jonathan Abysalh, Travis Jeannotte, Erik Held, Frank DeRosa, Michael Heartlein, Rebecca Powell
Filed: 25 Aug 19
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
18 Mar 20
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 11 Nov 19
Utility
Process of Preparing Mrna-loaded Lipid Nanoparticles
18 Mar 20
The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation.
Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Ball, Frank DeRosa, Michael Heartlein
Filed: 27 Aug 19
Utility
Lipid Formulations for Delivery of Messenger Rna
11 Mar 20
Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
Filed: 14 Nov 19
Utility
CFTR Mrna Compositions and Related Methods and Uses
12 Feb 20
Materials, formulations, production methods, and methods for delivery of CFTR mRNA for induction of CFTR expression, including in the mammalian lung are provided.
Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
Filed: 13 Aug 19
Utility
Ice-based Lipid Nanoparticle Formulation for Delivery of Mrna
5 Feb 20
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid.
Frank DeRosa, Michael Heartlein, Shrirang Karve
Filed: 10 Oct 19
Utility
Dry Powder Formulations for Messenger Rna
22 Jan 20
The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
Shrirang Karve, Frank DeRosa, Michael Heartlein, Zarna Patel, Ashish Sarode
Filed: 22 Jul 19
Utility
PolyAnionic Delivery of Nucleic Acids
15 Jan 20
Michael Heartlein, Frank DeRosa, Shrirang Karve
Filed: 6 Mar 18
Utility
Messenger Rna Vaccines and Uses Thereof
15 Jan 20
The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines.
Shrirang Karve, Zarna Patel, Ashish Sarode, Yi Zhang, Frank DeRosa, Michael Heartlein
Filed: 28 May 19
Utility
Mrna Therapeutic Compositions and Use to Treat Diseases and Disorders
25 Dec 19
Disclosed are compositions and methods for producing therapeutic fusion proteins in vivo.
Michael Heartlein
Filed: 23 May 19
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
23 Oct 19
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 2 Jul 19
Utility
Cleavable Lipids
16 Oct 19
Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use.
Braydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
Filed: 24 Jun 19
Utility
Subcutaneous Delivery of Messenger Rna
2 Oct 19
The present invention provides, among other things, methods of formulating nucleic acid-containing nanoparticles with an enzyme to afford efficient delivery of payload to a cell or tissue of interest via subcutaneous administration.
Shrirang Karve, Frank DeRosa, Zarna Bhavsar, Michael Heartlein
Filed: 9 Nov 17